IPM Take
Alzheimer’s diagnosis is no longer only a specialist-clinic question. It is becoming a laboratory-infrastructure question, and that shift will change who enters the pathway, who waits, and who is told that their symptoms are not yet clear enough to justify the next step.
The FDA clearance of Roche’s Elecsys pTau217 test, days after C2N’s PrecivityAD2 clearance for symptomatic adults as young as 40, marks a new phase. Blood tests are moving from research promise into clinical gatekeeping. That may reduce the dependence on PET scans and lumbar punctures, but it also creates a new responsibility: testing must not become another unequal filter in a disease where time, geography and specialist access already decide too much.
Executive Summary
Roche announced FDA clearance of Elecsys Phospho-Tau (217P) Plasma, a blood-based pTau217 test developed with Eli Lilly to aid assessment of amyloid pathology in people aged 55 and older with signs, symptoms or complaints of cognitive decline. Roche describes it as the first FDA-cleared single-biomarker blood test supporting both rule-in and rule-out assessment using the same validated cutoffs across primary and specialty care.
The clearance follows C2N Diagnostics’ announcement that FDA cleared PrecivityAD2 for adults aged 40 and older with cognitive symptoms, making it available to a younger symptomatic population than earlier cleared Alzheimer’s blood-test categories. C2N’s own site notes that the currently available PrecivityAD2 is still an LDT under CLIA regulations, while the FDA-cleared version is expected to become available in the coming months.
These tests are aids to evaluation, not stand-alone diagnoses. Results still require clinical interpretation alongside history, cognitive assessment, imaging or other confirmatory tools where appropriate. The access challenge is now shifting from whether blood biomarkers can perform, to whether health systems can use them responsibly and equitably.
Why it matters
- Patients / advocates: Earlier and less invasive testing can reduce uncertainty, but patients need counselling before and after results, especially when diagnosis changes treatment eligibility and family planning.
- Clinicians: Blood-based tools may help triage patients more efficiently, but they cannot replace clinical judgement or specialist follow-up.
- Diagnostics / pathology: The laboratory pathway is becoming central to Alzheimer’s care, which raises questions about quality standards, turnaround time and interpretation.
- Payers and public authorities: Coverage decisions will decide whether blood testing reduces access barriers or simply creates a new reimbursed/unreimbursed divide.
Alzheimer’s care has long been trapped between clinical suspicion and difficult confirmation. A family notices change, a primary-care doctor conducts a brief assessment, a specialist referral may take months, and definitive biomarker confirmation often depends on PET imaging or cerebrospinal-fluid testing that is expensive, invasive or simply unavailable in many settings.
Blood tests are now challenging that bottleneck. Roche’s Elecsys pTau217 clearance is particularly important because it is designed for use across a large installed base of laboratory instruments, which could bring amyloid-pathology assessment closer to routine clinical workflows. C2N’s PrecivityAD2 clearance adds another dimension by extending FDA-cleared use to symptomatic adults as young as 40, a group that can otherwise sit uncomfortably between psychiatric explanations, rare early-onset disease and slow diagnostic referral.
The policy risk is that the system begins using blood tests faster than it builds the counselling and confirmation infrastructure around them. A positive, negative or intermediate result does not exist in a vacuum; it can affect treatment decisions, trial eligibility, anxiety, family conversations and future planning. If testing is adopted unevenly, patients in better-resourced systems will move faster through the pathway while others remain stuck in the old diagnostic fog.
For IPM, the story is not that blood tests have “solved” Alzheimer’s diagnosis. The story is that Alzheimer’s precision medicine is now entering ordinary care through laboratories, and ordinary care is not yet prepared for the power this gives it.
